News Search Results
Jan 13, 2026, 08:00 ET Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
AI-Optimized Platform): A Multi-Modal Computational Platform for Informing Target and Indication Selection, Biomarker Readout, and Patient Stratification in CNS Drug Development TH202
More news about: Johnson & Johnson
Jan 13, 2026, 07:30 ET Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
neurofilament light chain (NfL) levels. These results validate the capability of our proprietary SCAD™ delivery platform for central nervous system (CNS) in humans.Dr. Long-Cheng Li, Founder and CEO of Ractigen Therapeutics, emphasized Ractigen's dedication to advancing treatments for ALS: "The
More news about: Ractigen Therapeutics
Jan 12, 2026, 16:26 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for December 2025
NEW YORK, Jan. 12, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $90.5 billion as of December 31, 2025, a decrease of $1.4 billion from assets under management
More news about: Cohen & Steers, Inc.
Jan 12, 2026, 11:15 ET Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
does not exhibit the GABA receptor activity seen with ezogabine and other antiseizure medicines (ASMs), which contribute to central nervous system (CNS) adverse effects and their poor tolerability in the clinic. Opakalim is being developed to address the significant unmet medical need that exists for
More news about: Biohaven Ltd.
Jan 12, 2026, 09:00 ET Neurelis Provides Business Update Highlighting Transformational 2025 Results
with epilepsy.These 2025 developments position the Company to sustain the momentum of VALTOCO, advance its CNS pipeline, and pursue additional products that leverage its CNS-focused commercial engine, supported by a strong financial profile.About NeurelisNeurelis, Inc.,
More news about: Neurelis, Inc.
Jan 12, 2026, 09:00 ET Cohen & Steers Appoints Diana Shieh to Lead Private Real Estate Operations and Asset Management
NEW YORK, Jan. 12, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today the appointment of Diana Shieh as Chief Operating Officer (COO) and Head of Asset Management for Cohen & Steers' Private Real Estate
More news about: Cohen & Steers, Inc.
Jan 12, 2026, 09:00 ET Mandara Biopharma Files IND with the FDA to Advance Dronabinol Oral Solution Formulation for Alzheimer's Agitation
/PRNewswire/ -- Mandara Biopharma Inc., a privately held U.S.-based biopharmaceutical company focused on novel therapies for central nervous system (CNS) disorders, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate
More news about: Mandara Biopharma Inc.
Jan 12, 2026, 07:03 ET SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer's Disease
immune response. The company aims to develop disease-modifying treatment options for Alzheimer's disease, Parkinson's disease, and other devastating CNS diseases. For more information, please visit
More news about: SciNeuro Pharmaceuticals
Jan 12, 2026, 07:00 ET Corero Network Security Delivers Strong Full-Year 2025 Performance Driven by Global Customer Wins and Expanding Enterprise Adoption
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today provided a year-end business
More news about: Corero Network Security
Jan 12, 2026, 06:30 ET Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Jan 12, 2026, 03:00 ET Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
in 1947 and headquartered in Seoul, South Korea, is a pharmaceutical company with core expertise in ophthalmology, hepatology, gastroenterology, and CNS disorders. As part of its global expansion strategy, Samil operates overseas subsidiaries in North America, Vietnam, and Japan. Through ongoing partnerships
More news about: Formosa Pharmaceuticals Inc.,
Jan 09, 2026, 07:30 ET Avista Therapeutics Expands AI Gene Therapy Platform to Break Barriers in the Delivery of Genetic Medicines
create impactful therapies, with a clinical pipeline encompassing preclinical stage programs for XLRS, PRPF31, and other retinal diseases, as well as CNS indications."About Avista TherapeuticsAvista (
More news about: Avista Therapeutics
Jan 08, 2026, 20:13 ET INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm
[email protected] COMPANY: Anavex Life Sciences Corp. is a clinical-stage biotech developing targeted therapies for neurodegenerative and CNS disorders like Alzheimer's and Parkinson's.THE ALLEGED WRONGDOING:On November 14, 2025, Anavex announced that the Committee
More news about: Edelson Lechtzin LLP
Jan 08, 2026, 10:33 ET Perceptive Discovery Announces Strategic Expansion Across Radiochemistry, Cell Assay Capabilities, and In Vitro Infrastructure to Strengthen Integrated Preclinical Workflows
translational solutions that bridge scientific innovation to early-phase clinical success. With deep expertise in radiochemistry, in-vivo imaging, oncology and CNS models, dosimetry, assay development, and radioligand therapy, Perceptive Discovery provides integrated workflows that generate high-quality, decision-ready
More news about: Perceptive Discovery
Jan 08, 2026, 10:00 ET Cumulus Neuroscience Appoints Ricardo Sáinz Fuertes, MD as New Board Chair
Cumulus. "Ruth is a pioneer in the digital biomarker space, having seen the promise of these novel tools to address multiple challenges associated with CNS drug discovery, from the lack of translation from pre-clinical models to human studies, to the limitations associated with traditional 'snapshot in time'
More news about: Cumulus Neuroscience
Jan 08, 2026, 09:31 ET DR. ANDREW WEIL AND DAUGHTER DIANA WEIL UPDATE ANTI-INFLAMMATORY FOOD PYRAMID FOR 2026 AFTER 20 YEARS
Andrew Weil, M.D., world-renowned pioneer in integrative medicine, and Diana Weil, MS, CNS, LDN, today unveiled a modern redesign of Dr. Weil's Anti-Inflammatory Food Pyramid - its first major update in 20 years, commemorating two decades
More news about: Weil Nutrition Corner™
Jan 08, 2026, 07:00 ET Corero Network Security Appoints Michelle Ragusa-McBain as Vice President of Channel Sales
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today announced the appointment of
More news about: Corero Network Security
Jan 08, 2026, 03:30 ET STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications
discovery of breakthrough small molecule drugs that precisely reprogram cells through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases.STORM's lead product, STC-15, is the first RNA modifying enzyme inhibitor to enter human clinical development. STC-15 is currently being
More news about: STORM Therapeutics
Jan 07, 2026, 16:17 ET Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor that demonstrated significant reductions in cardiovascular risk factors in a recently reported Phase 2 trial. In addition,
More news about: Eli Lilly and Company
Jan 07, 2026, 10:32 ET How $594B in Precision Tech is Cracking the Metastatic Cancer Code
median overall survival of 11.3 months in DTH-positive patients versus 4.7 months in DTH-negative patients, with 100% clinical benefit rate in evaluable CNS metastasis patients. The Bria-IMT regimen was well tolerated with no treatment-related discontinuations due to adverse events across all studies. Greenwich
More news about: USA News Group
Jan 07, 2026, 09:00 ET Cohen & Steers Appoints Kikuo Shirose as Head of Japan
TOKYO and NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that Kikuo Shirose has joined Cohen & Steers as Representative Director of Cohen & Steers Japan Limited. Mr. Shirose will lead all
More news about: Cohen & Steers, Inc.
Jan 07, 2026, 08:50 ET Aspen Neuroscience Appoints Chief Commercial Officer Lisa Johnson-Pratt, M.D. and Welcomes Revati Shreeniwas, M.D., FCCP as Chief Medical Officer to Accelerate Late‑Stage Development and Commercial Readiness
registrational programs where she has advanced assets from early stage/IND through global approvals. Her experience spans neurology and neurodegeneration in the CNS arena and includes contribution to the approval and commercialization of therapies such as RYTARY® (Parkinson's disease), SUNOSI®, Esbriet®, and TRACLEER®.Dr.
More news about: Aspen Neuroscience, Inc.
Jan 07, 2026, 07:00 ET AL-S Pharma to present at the upcoming J. P. Morgan 2026 Annual Healthcare Conference on Thursday, January 15
investigational human-derived antibody directed against misfolded superoxide dismutase 1 (SOD1) designed to inhibit the spread of SOD1 pathology in the CNS of ALS patients. AP-101 received orphan drug designations from FDA, EMA and Swissmedic. The Phase 2 study evaluated safety, tolerability, pharmacodynamic
More news about: AL-S Pharma AG
Jan 06, 2026, 19:00 ET コーヘン&スティアーズ・ジャパン代表取締役社長に白勢菊夫を任命
https://www.cohenandsteers.comティッカー：NYSE: CNS将来の見通しに関する記述について本プレスリリースおよびコーヘン&スティアーズが行うその他の記述には、1933年証券法（改正後）第27A条および1934年証券取引所法（改正後）第21E上の意義の範囲内における将来の見通しに関する記述が含まれている場合
More news about: Cohen & Steers, Inc.
Jan 06, 2026, 08:01 ET TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
already been completed and that the formulation has shown appreciable safety in Phase I clinical trials in patients with non-central nervous system (CNS) cancers, these results support advancing TTX-MC138 to future clinical evaluation in patients with GBM."This research represents an important
More news about: TransCode Therapeutics, Inc.